Key Highlights

  • Second-quarter net Revenue reached $740.3 million, up 12.7% year over year and 15.9% organic, but the company swung to a net loss of $145.3 million.
  • The net loss was driven by a $144.2 million Goodwill impairment, and adjusted EBITDA declined 3.2% to $132.0 million.
  • Management cut full-year 2026 adjusted EBITDA guidance to $490 million to $520 million from a prior $680 million to $730 million.
  • The reduction cited the divestiture of the diabetes business, complexity in a West Coast capitated contract, a manufacturer price increase and other portfolio actions.

AdaptHealth (NASDAQ:AHCO), a provider of home medical equipment and healthcare-at-home services, posted strong revenue growth in its latest quarter, but a fuller look at the results shows that growth was overshadowed by a goodwill impairment, Margin pressure and a sharply lowered profit outlook. The question of whether the company deserves a fresh look must be weighed against these real near-term challenges.

AdaptHealth delivers home medical equipment, supplies and related services to millions of patients across the United States, spanning sleep therapy such as CPAP devices, respiratory care, and general home medical equipment. Its Business benefits from favorable demographics and the shift of care into the home, but it operates in a complex reimbursement environment and has grown partly through acquisitions, which it is now rationalizing.

Latest Developments

In its second-quarter 2026 results, AdaptHealth reported net revenue of $740.3 million, up 12.7% year over year and 15.9% organic, but it swung to a net loss of $145.3 million, driven by a $144.2 million goodwill impairment, and adjusted EBITDA declined 3.2% to $132.0 million. Most significantly, management cut full-year 2026 adjusted EBITDA guidance to $490 million to $520 million from a prior $680 million to $730 million, citing the impact of divesting its diabetes business, which is being sold to Cardinal Health, along with complexity in a West Coast capitated contract, a manufacturer price increase and other portfolio actions. The diabetes business is being reclassified as discontinued operations.

Financial and Business Position

AdaptHealth's strong revenue growth reflects genuine Demand for home-based care, but the goodwill impairment, margin pressure and dramatic guidance cut point to significant execution and portfolio challenges. The divestiture of the diabetes business, the capitated-contract complexity and cost pressures are reshaping the company's profit profile, and the magnitude of the EBITDA guidance reduction underscores the near-term difficulties. The underlying healthcare-at-home model has favorable long-term drivers, but the company must work through these portfolio and margin issues to restore its profitability trajectory.

Stock-Market Context

The company carries a strong-buy analyst rating, an optimistic stance that contrasts with the goodwill Impairment and the steep guidance cut. The fresh-look case would require the company to stabilize its margins, successfully divest the diabetes business and simplify its portfolio, and return to profitable growth; the cautionary case is that the large guidance reduction, the impairment and the reimbursement and contract complexities signal meaningful execution risk.

What Investors Should Watch

Investors may focus on adjusted EBITDA and margin trends against the lowered guidance, the completion and impact of the diabetes-business divestiture, resolution of the West Coast capitated-contract issues, organic revenue growth across sleep, respiratory and home medical equipment, and the company's Debt and cash flow. Evidence that AdaptHealth can stabilize margins and simplify its portfolio while sustaining revenue growth would be needed to justify a fresh look after the sharp reset.

The healthcare-at-home model AdaptHealth operates benefits from powerful long-term drivers, including an aging population, the rising prevalence of chronic conditions requiring home-based care, and the broader shift of healthcare delivery into the home, which supports durable demand for its equipment and services. The near-term difficulties, however, are substantial. The goodwill impairment reflects a reassessment of the value of past acquisitions, the divestiture of its diabetes business reshapes the portfolio and the revenue base, and complexity in a capitated contract along with cost pressures compressed margins, together prompting the steep guidance cut. For investors, the reality is that the quarter revealed meaningful near-term pressures, and the case for the stock depends on the company stabilizing its margins, successfully completing the diabetes divestiture, simplifying its portfolio, and demonstrating that it can convert its strong revenue growth into recovering profitability.